Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial.
Year: 2009
Type: conference-abstract
Source: Cancer Research
Institutions: Royal Marsden NHS Foundation Trust, Institute of Cancer Research, University of Miami, University of Southern California, USC Norris Comprehensive Cancer Center, Centre Hospitalier Universitaire de Besançon, Instituto Nacional de Enfermedades Neoplásicas, GlaxoSmithKline (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2088573877